

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

02 AUG 22 PM 3: 34

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name C. McClain Haddow			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 2921 Mother Well Court City Herndon State/Zip (or Country) VA 20171			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name C. McClain Haddow	Telephone (703) 471-5210	E-mail (optional) machaddow@erols.com	5. Senate ID # 17248-12
7. Client Name <input type="checkbox"/> Self Mylan Laboratories, Inc			6. House ID # 30054000

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input checked="" type="checkbox"/> >> \$ \$60,000.00 Income (nearest \$20,000)	\$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of
	<input type="checkbox"/> Method A. Reporting amounts using LDA definition
	<input type="checkbox"/> Method B. Reporting amounts under section 603 of the Internal Revenue Code
	<input type="checkbox"/> Method C. Reporting amounts under section 162 of the Internal Revenue Code

Signature


Date 8/14/2002Printed Name and Title C. McClain Haddow - President

Pa

Registrant Name: C. McClain Haddow 00020371864

Client Name: Mylan Laboratories, Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.


- 15. General issue area code HCR (one per page)
- 16. Specific Lobbying issues
H.R.1685, Generic Drugs Access Act of 2001, Generic drug access
S. 812, Greater Access to Affordable Pharmaceuticals, Generic drug access

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Haddow, C. McClain	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/14/2002

Printed Name and Title C. McClain Haddow - President Pa

Registrant Name: C. McClain Haddow

00020371865

Client Name: Mylan Laboratories, Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

- H.R.1063, Drug Competition Act of 2001, Generic Drug Access to Market**
- H.R.1512, Medicare Extension of Drugs to Seniors (MEDS) Act of 2001, Generic Drug access to market**
- H.R.1530, Prescription Drug Competition Act of 2001, Generic Drug access to market**
- H.R.1685, Generic Drugs Access Act of 2001, Generic Drug access to market**
- H.R.339, Medicare Outpatient Prescription Drug Coverage Act of 2001, Generic Drug access to market**
- S.10, Medicare Prescription Drug Coverage Act of 2001, Generic Drug access to market**
- S.186, Generic Pharmaceutical Access and Choice for Consumers Act of 2001, Generic Drug access to market**
- S.358, Medicare Prescription Drug and Modernization Act of 2001, Generic Drug access to market**
- S.754, Drug Competition Act of 2001, Generic Drug access to market**
- S.812, Greater Access to Affordable Pharmaceuticals Act of 2001, Generic Drug access to market**

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Haddow, C. McClain	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *C. McClain Haddow*

Date 8/14/2002

Printed Name and Title C. McClain Haddow - President

Pa

Registrant Name: **C. McClain Haddow**

00020371866

Client Name: **Mylan Laboratories, Inc**

Item	Description	Data
16	Lobbying Issues	S.925, Medicare Extension of Drugs to Seniors (MEDS) Act of 2001, Generic access to market
16	Lobbying Issues	S.RES.74, A resolution expressing the sense of the Senate regarding consideration of legislation providing medicare beneficiaries with outpatient prescription drug coverage, Generic Drug access to market

